A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Phase 1/2 Terminated 7 enrolled Shandong Cancer Hospital and Institute

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.

Timeline

Start: 2020-11-12
Primary completion: 2021-11-20
Completion: 2021-11-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Background	Docetaxel	Small molecule	—	—
Background	Pemetrexed	Small molecule	—	—

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications